Answers are grounded in this paper and cite their sources.
In 1999 the US Food and Drug Administration published a regulation in an attempt to ensure the legibility of OTC drugs, specifying, among other things, a minimum type size of 6 points. This is problematic because different typefaces of the same size vary widely in type heights and, presumably, legibility. We hypothesized that specifying a minimum x‐height, the height of the lowercase x, would produce more consistent legibility than the minimum type size specified within the regulation. Twenty‐six subjects viewed two groups of typefaces using the Lockhart Legibility Instrument to quantify legibility. The first group contained typefaces that were all 6 points, but, by nature of their design, varied greatly in their x‐heights. The second group was made from the same set of typefaces, but these were manipulated so that their x‐heights were equal to the average x‐height of group 1. A likelihood ratio test indicated that the group that varied in x‐height, group 1, produced significantly more variable results than the group with equal x‐heights, group 2. This indicates that specifying a minimum type size may not be the best approach for producing consistent legibility.
No takes yet. Share an insight, caveat, or question.
Bix et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: